A Phase II Study of Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma Without MGMT Promoter Methylation.
Phase of Trial: Phase II
Latest Information Update: 02 Nov 2018
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary) ; Temozolomide
- Indications Glioblastoma; Glioma; Gliosarcoma
- Focus Therapeutic Use
- 24 Oct 2018 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 27 May 2016 Planned End Date changed from 1 Mar 2017 to 1 Mar 2019.